UB Paderborn / Katalog / Suche / in CDI

Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

PloS one, 2023-02, Vol.18 (2), p.e0281580-e0281580

2023

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

Frontiers in immunology, 2023-03, Vol.14, p.1129459-1129459

2023

Link zum Volltext

Verfügbarkeit prüfen

Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients

Cancer medicine (Malden, MA), 2020-11, Vol.9 (22), p.8571-8578

2020

Link zum Volltext

Verfügbarkeit prüfen

Informative Censoring-A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data

Life (Basel, Switzerland), 2023-01, Vol.13 (1), p.210

2023

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group

Clinical infectious diseases, 2003-09, Vol.37 (5), p.613-627

2003

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of patient population differences and genomic variation in efavirenz therapy

AIDS (London), 2008-09, Vol.22 (14), p.1709-1717

2008

Link zum Volltext

Verfügbarkeit prüfen

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

AIDS (London), 2010-07, Vol.24 (11), p.1781-1784

2010

Link zum Volltext

Verfügbarkeit prüfen

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

The lancet HIV, 2017-07, Vol.4 (7), p.e284-e294

2017

Link zum Volltext

Verfügbarkeit prüfen

High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group

PloS one, 2015-07, Vol.10 (7), p.e0131001-e0131001

2015

Link zum Volltext

Verfügbarkeit prüfen

Development of National and Multiagency HIV Care Quality Measures

Clinical infectious diseases, 2010-09, Vol.51 (6), p.732-738

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

Journal of clinical and translational science, 2023, Vol.7 (1), p.e40-e40, Article e40

2023

Link zum Volltext

Verfügbarkeit prüfen

Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected Persons

Clinical infectious diseases, 2005-10, Vol.41 (7), p.1045-1048

2005

Link zum Volltext

Verfügbarkeit prüfen

The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity

The Journal of infectious diseases, 2019-08, Vol.220 (Supplement_2), p.S33-S41

2019

Link zum Volltext

Verfügbarkeit prüfen

Preserving the Future of Infectious Diseases: Why We Must Address the Decline in Compensation for Clinicians and Researchers

Clinical infectious diseases, 2023-11, Vol.77 (10), p.1387-1394

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis

Antimicrobial Agents and Chemotherapy, 2005-03, Vol.49 (3), p.952-958

2005

Link zum Volltext

Verfügbarkeit prüfen

Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Clinical infectious diseases, 2004-09, Vol.39 (5), p.609-629

2004

Link zum Volltext

Verfügbarkeit prüfen

Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Clinical infectious diseases, 2014-01, Vol.58 (1), p.1-10

2014

Link zum Volltext

Verfügbarkeit prüfen

Collaborative Strategies for Antimicrobial Stewardship Programs: Navigating Financial and Regulatory Landscapes

Clinical infectious diseases, 2023-11

2023

Link zum Volltext

Verfügbarkeit prüfen

A mobile health intervention in HIV primary care: supporting patients at risk for ART non-adherence

HIV research & clinical practice, 2020-12, Vol.21 (5), p.140-150

2020

Link zum Volltext

Verfügbarkeit prüfen

Design aspects of a case-control clinical investigation of the effect of HIV on oral and gastrointestinal soluble innate factors and microbes

PloS one, 2014-11, Vol.9 (11), p.e112901-e112901

2014

Link zum Volltext

Verfügbarkeit prüfen

Lipid management in patients who have HIV and are receiving HIV therapy

Endocrinology and metabolism clinics of North America, 2009-03, Vol.38 (1), p.207

Aberg, Judith A

2009

Link zum Volltext

Verfügbarkeit prüfen

Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial

Addiction science & clinical practice, 2022-05, Vol.17 (1), p.28-15, Article 28

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047

AIDS (London), 2002-03, Vol.16 (4), p.569-577

2002

Link zum Volltext

Verfügbarkeit prüfen

Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Clinical infectious diseases, 2021-12, Vol.73 (11), p.e3572-e3605

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients

Informative Censoring-A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group

Clinical impact of patient population differences and genomic variation in efavirenz therapy

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group

Development of National and Multiagency HIV Care Quality Measures

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

An inflammatory cytokine signature predicts COVID-19 severity and survival

Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected Persons

The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity

Preserving the Future of Infectious Diseases: Why We Must Address the Decline in Compensation for Clinicians and Researchers

Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis

Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Collaborative Strategies for Antimicrobial Stewardship Programs: Navigating Financial and Regulatory Landscapes

A mobile health intervention in HIV primary care: supporting patients at risk for ART non-adherence

Design aspects of a case-control clinical investigation of the effect of HIV on oral and gastrointestinal soluble innate factors and microbes

Lipid management in patients who have HIV and are receiving HIV therapy

Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047

Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Suchergebnisse filtern